{
  "patent_number": "US 8957079",
  "country": "US",
  "title": "How Ibrutinib-like Molecules Block Cancer-Causing Proteins",
  "original_title": "Inhibitors of Bruton's tyrosine kinase",
  "summary": "A chemical design for molecules that permanently latch onto and disable a specific protein called Btk, which is often responsible for the growth of certain blood cancers.",
  "what_it_does": "This patent describes a class of chemical compounds designed to bind irreversibly to a protein known as Bruton's tyrosine kinase (Btk). By using a specific chemical component called a Michael acceptor, these molecules form a permanent covalent bond with the Btk protein, effectively shutting it down. This prevents the protein from signaling cancer cells to survive and multiply. For example, in patients with B-cell lymphomas, this mechanism stops the rogue cells from receiving the instructions they need to keep growing.",
  "what_it_does_not_cover": [
    "Does not cover the Btk protein itself, but rather specific synthetic chemical structures that target it.",
    "Does not cover reversible inhibitors that bind and release from the protein.",
    "Does not cover non-Michael acceptor based inhibitors that lack the specific covalent binding mechanism described.",
    "Does not cover general methods for treating cancer that do not utilize the specific chemical structures defined in the claims."
  ],
  "filed": "2012-10-17",
  "granted": "2015-02-17",
  "expires": null,
  "status": "active",
  "holder": "Pharmacyclics LLC",
  "holder_url": "https://patentbrief.org/company/pharmacyclics-llc",
  "inventors": [
    {
      "name": "Zhengying Pan",
      "url": "https://patentbrief.org/inventor/zhengying-pan"
    },
    {
      "name": "Erik Verner",
      "url": "https://patentbrief.org/inventor/erik-verner"
    },
    {
      "name": "Lee Honigberg",
      "url": "https://patentbrief.org/inventor/lee-honigberg"
    }
  ],
  "times_cited": 33,
  "tags": [
    "biotech",
    "pharmaceutical"
  ],
  "abstract": "Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure: Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.",
  "url": "https://patentbrief.org/patent/us/8957079/pomalyst-pomalidomide",
  "markdown_url": "https://patentbrief.org/patent/us/8957079/pomalyst-pomalidomide/md",
  "google_patents_url": "https://patents.google.com/patent/US8957079",
  "relatedPatents": []
}